Pharmaceuticals Company Announces Promising Results In Breast Cancer Cell Growth Inhibition
Shuttle Pharma's Selective HDAC Inhibitor Demonstrates Promising Results in Breast Cancer Cell Growth Inhibition.
Disclaimer: The following article discusses research findings as reported in the scientific journal PLOS ONE. The content is intended for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for medical concerns or treatments.
Real-time information is available daily at https://stockregion.net
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), known for its innovative approach in enhancing cancer treatments through radiation therapy, has announced promising developments with one of its pre-clinical assets, SP-1-303. The selective histone deacetylase (HDAC) inhibitor has demonstrated substantial growth inhibition of estrogen receptor-positive breast cancer cells (ER+ BC) by activating the ataxia-telangiectasia mutated (ATM) protein and modulating estrogen receptor (ER) expression. These findings were published in the peer-reviewed journal, PLOS ONE.
SP-1-303: Targeted Mechanism and Research Findings
Histone deacetylase inhibitors (HDACi) are a class of compounds that play a critical role in cancer therapy. They work by influencing gene expression, which can lead to cancer cell death, increased sensitivity to radiation, protection of normal tissues, and activation of the immune system. HDAC inhibitors can be particularly effective when combined with other therapeutic modalities, such as immune checkpoint blockers. SP-1-303 was discovered and synthesized by Dr. Scott Grindrod, Shuttle Pharma’s Principal Scientist. It belongs to the selective Class I HDAC inhibitors category, specifically targeting HDAC1, 3, and 6. The compound exhibits direct cellular toxicity towards ER+ BC cells and shows potential for use in combination therapies due to its ability to increase PD-L1 expression over time.
The research leading to these findings was a collaborative effort between Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Grindrod. Their manuscript titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth" elaborates on the dual functionality of SP-1-303 as both an HDAC inhibitor and ATM activator. ATM proteins are crucial for DNA repair and cell cycle control. By activating ATM, SP-1-303 enhances the DNA damage response, leading to increased cancer cell death. Additionally, the modulation of estrogen receptor expression by SP-1-303 interferes with critical signaling pathways in ER+ BC cells, further inhibiting their growth.
Dr. Anatoly Dritschilo, CEO of Shuttle Pharmaceuticals, emphasized that SP-1-303's dual-targeting approach offers a compelling strategy for cancer treatment. The selective inhibition of Class I HDACs, combined with ATM activation, provides a synergistic effect that could enhance the therapeutic outcomes for patients with ER+ BC. Dr. Dritschilo highlighted the importance of further preclinical evaluations to explore SP-1-303's full potential as a therapeutic agent.
The Role of Shuttle Pharmaceuticals in Cancer Treatment Innovation
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals has been at the forefront of developing specialized pharmaceuticals designed to improve cancer treatment outcomes, particularly for patients undergoing radiation therapy (RT). The company’s mission is to develop novel therapies that enhance the effectiveness of RT while minimizing its adverse effects. Radiation therapy is a cornerstone in cancer treatment, known for its ability to target and destroy cancer cells. However, traditional RT can also damage surrounding healthy tissues, leading to various side effects. Shuttle Pharma's approach involves the development of radiation sensitizers like SP-1-303, which can make cancer cells more susceptible to radiation damage while protecting normal tissues. This strategy aims to improve cure rates, extend patient survival, and enhance the quality of life.
Shuttle Pharma's commitment to advancing cancer treatment is evident through its investment in rigorous research and development. By collaborating with leading academic institutions and leveraging cutting-edge technology, the company seeks to bring innovative solutions to clinical practice. SP-1-303 represents one of the many promising candidates in Shuttle Pharma’s pipeline, showcasing the potential of targeted therapies in revolutionizing cancer care.
The promising results from the research on SP-1-303 highlight the potential of selective HDAC inhibitors in the treatment of estrogen receptor-positive breast cancer. By activating ATM and modulating estrogen receptor expression, SP-1-303 demonstrates growth inhibition of cancer cells, paving the way for new therapeutic strategies. Shuttle Pharmaceuticals’ dedication to improving radiation therapy outcomes continues to push the boundaries of cancer treatment, offering hope for better patient care and improved survival rates.
Disclaimer: The information presented in this article is based on the findings published in PLOS ONE and is intended for educational purposes only. It should not be construed as medical advice. For personalized medical guidance, please consult a healthcare professional.
Real-time information is available daily at https://stockregion.net